Head-to-head evidence
Evogliptin vs Trelagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Evogliptin · Suganon
Developed by Dong-A ST
NCT02949193 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial (n=222) comparing evogliptin against sitagliptin, both added to metformin. The prespecified non-inferiority comparison for the primary endpoint, HbA1c change at 24 weeks, was met: the between-group difference and its confidence interval stayed within the non-inferiority range.
Trelagliptin · Zafatek
Developed by Takeda Pharmaceutical Company
NCT03940183 · Phase 3 · completed
The trial randomized 254 participants to trelagliptin or placebo and used quadruple blinding. Its primary endpoint was the surrogate measure of change in HbA1c at week 24, but results were not posted, so whether the comparison favored trelagliptin is unknown.
Next expected readout: December 2026 · NCT07073768 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Evogliptin's landscape · Trelagliptin's landscape